Loading…
← CockpitCompetitor Analysis › 300685.SZ Amoy Diagnostics Co., Ltd. Class AOpen in the cockpit ↗

Amoy Diagnostics Co., Ltd. Class A300685.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Medical Specialties

Chinese leader in companion-diagnostic tests that identify gene mutations to guide targeted cancer therapy.

≈ A Chinese Foundation Medicine/QIAGEN for companion diagnosticsMomentum strong 70
Mkt cap
$1.01B
US dollars, full cap
Free float
67%
of shares outstanding
$/day
$27.3M
20-day average traded
Fwd P/E
19.3×
forward earnings
ROIC−WACC
+29.6 pp
WACC 8.7%
Hurdle
-5 pp
Req g minus delivered
Next earnings
146 days
13 Apr 2027
Close · CNYCN¥17.58
1D-2.3%
1W-9.3%
1M-6.9%
3M-11.0%
6M-14.8%
YTD-14.1%
1Y-23.7%
ATR %4.3%
52w lowhigh27.1% off high

What Amoy Diagnostics does

Chinese leader in companion-diagnostic tests that identify gene mutations to guide targeted cancer therapy.

Sells reagent kits that hospitals and labs use up one test at a time, so revenue follows the number of cancer patients tested rather than equipment purchases. Many kits are approved by China's drug regulator alongside specific targeted drugs, so a new drug approval can create demand for a matching test.

In one line: A Chinese Foundation Medicine/QIAGEN for companion diagnostics.

Products and services

  • EGFR/oncogene mutation test kits
  • NGS-based cancer panels

Customers

  • Hospitals/oncology labs
  • Pharmaceutical partners (drug trials)

Where it sits in the supply chain

  • Health Care
  • In-vitro diagnostics
  • Oncology companion diagnostics…

What could go right

  • Targeted cancer therapy adoption growth

What could go wrong

  • Reimbursement/pricing pressure on oncology testing

Moat: narrow (regulatory licence, IP / patents). Companion-diagnostic approvals tied to specific approved cancer drugs create lock-in.

Headquarters: Xiamen, Fujian, China · Founded: 2003 · Employees: 1,175

Named competitors

Amoy Diagnostics at a glance

Size Amoy Diagnostics (300685.SZ) is a China Health Care company (Medical Specialties) with a market value of $1.01B, the 2141st largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥17.58 on 18 Nov 2026.

Performance Over six months the shares fell 14.8%, against -6.8% for the median peer and -20.0% for the China market (cap-weighted) — 7th lowest of 20 in its peer set.

Growth Revenue grew 6.7% over the last twelve months (peer median +11.0%); the operating margin is 33.8% (peer median 11.0%).

Valuation It trades at 19.3× forward earnings against a peer median of 18.6× (6th most expensive of 13).

Price implies For today's price to make sense, revenue must grow about 5% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is -5 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 29.6 points above its cost of capital (8.7% WACC).

Next results Next results expected around 13 Apr 2027 (exchange calendar; dates can move).

Relative performance

809010011021 May 202621 Aug 202618 Nov 2026Peer median 92300685.SZ 86
Six months, rebased to 100: Amoy Diagnostics against the median of its 20 peers (local-currency closes).

Amoy Diagnostics financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥1.20BCN¥1.19BCN¥1.11BCN¥1.04BCN¥840M
Revenue growth—+7%+6%+24%—
Gross profitCN¥988MCN¥931MCN¥889MCN¥825MCN¥651M
EBITDAn/aCN¥420MCN¥334MCN¥328MCN¥196M
Net incomeCN¥346MCN¥361MCN¥255MCN¥261MCN¥264M
Free cash flowCN¥346MCN¥311MCN¥316MCN¥261MCN¥80.9M
Capital expenditureCN¥60.2MCN¥70.2MCN¥40.2MCN¥44.9MCN¥78.3M
Total debtCN¥168MCN¥124MCN¥91.6MCN¥108MCN¥53.6M

Quarterly statements and history in the cockpit →

Amoy Diagnostics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-40%-20%0%+20%3002066523301021600055CBLLEUZCSTL300143IRMD7730SIBN3046688622301101SFL2141507780290650300685.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Amoy Diagnostics is the large dot.

Fundamentals: revenue growth against valuation

0%+10%+20%20×40×3002066523EUZ300143IRMD77303046301101SFLIART2141507780300685.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Amoy Diagnostics is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%+60%0%20%40%60%3002066523301021EUZCSTL300143IRMD77303046SFL214150290650300685.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Amoy Diagnostics is the large dot.

Amoy Diagnostics competitors and peer comparison

Head to head with its named competitors (300685.SZ vs QGEN vs BNR.DE)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Amoy Diagnostics 300685.SZ$1.01B-15%+7%34%19.3×4.9%
Qiagen QGEN$10.2B+41%+2%25%19.5×8.6%
Brenntag BNR.DE$9.19B+2%0%5%14.0×0.7%

How Amoy Diagnostics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Amoy Diagnostics against its 20 peers (data as of 18 Nov 2026)
Measure300685.SZPeer medianRank in peer set
1-month return-6.9%-1.9%7th lowest of 21
6-month return-14.8%-6.8%7th lowest of 20
Distance from 52-week high-27.1%-28.9%10th highest of 21
Revenue growth (TTM)+6.7%+11.0%8th lowest of 20
Operating margin33.8%11.0%3rd highest of 21
Forward P/E19.3×18.6×6th most expensive of 13
Growth the price implies (Req g, 7 yrs)4.9%7.3%6th least demanding of 15
Growth delivered (Del g)+10.4%+11.9%7th lowest of 15
Hurdle (Req g minus delivered)-5.4 pp-2.6 pp5th least demanding of 15
ROIC minus cost of capital+29.6 pp+2.8 pp2nd highest of 20

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Amoy Diagnostics 300685.SZChina$1.01B-15%+7%34%19.3×4.9%+10.4%
Edan Instruments 300206.SZChina$1.00B-19%+14%17%18.0×6.9%-2.9%
PHC 6523.TJapan$1.02B+34%+3%8%7.5×-4.0%+3.5%
Inno Laser Technology 301021.SZChina$1.03B-33%+17%9%n/a50.8%+8.6%
Beijing Wandong Medical Technology 600055.SSChina$1.03B-26%-11%-33%n/an/an/a
Ceribell CBLLUnited States$995M+42%+31%-70%n/an/an/a
Eckert & Ziegler EUZ.DEGermany$1.03B-2%+4%26%18.5×7.7%+12.1%
Castle Biosciences CSTLUnited States$1.03B+67%+10%-7%n/a57.7%+40.6%
INKON Life Technology 300143.SZChina$985M-23%+22%12%50.3×10.7%+12.9%
IRadimed IRMDUnited States$1.05B-9%+11%32%34.3×18.5%+21.5%
Mani 7730.TJapan$965M-7%+10%30%19.9×3.3%+13.9%
SI-BONE SIBNUnited States$1.06B+59%+14%-8%n/an/an/a
JINS 3046.TJapan$963M-8%+14%10%18.7×-6.1%+11.7%
Guangzhou Hexin Instrument 688622.SSChina$1.06B+21%-29%-74%n/an/an/a
Mingyue Optical Lens 301101.SZChina$1.07B-4%+14%25%31.6×8.8%+8.8%
Safilo SFL.MIItaly$953M+42%-4%9%15.8×1.3%+4.7%
Integra LifeSciences IARTUnited States$1.08B-10%+1%12%6.0×5.9%+3.6%
CLASSYS 214150.KSSouth Korea$1.08B-60%+16%43%13.7×-9.2%+34.5%
Menicon 7780.TJapan$944M+26%+6%9%20.9×n/an/a
Freenome FRNMUnited States$1.08Bn/an/a36%n/an/an/a
L&C BIO 290650.KSSouth Korea$943M-37%+65%20%n/a32.6%+21.0%

Questions

Who are Amoy Diagnostics's main competitors?
Named competitors: Foundation Medicine (Roche) (private or unlisted), QIAGEN (QGEN), Burning Rock Biotech (BNR.DE). The cockpit's measured peer set (industry) also includes Edan Instruments (300206.SZ), PHC (6523.T), Inno Laser Technology (301021.SZ), Beijing Wandong Medical Technology (600055.SS), Ceribell (CBLL), Eckert & Ziegler (EUZ.DE).
Is Amoy Diagnostics expensive compared with its peers?
On forward p/e it trades at 19.3× against a peer median of 18.6×, 6th most expensive of 13 in its peer set. For today's price to make sense, revenue must grow about 5% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is -5 pp: the price already allows for a slowdown.
How has Amoy Diagnostics stock performed?
Over six months to 18 Nov 2026 the shares returned -14.8% against -6.8% for the median peer; over one year -23.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.